Imagine facing a rare blood cancer like myelofibrosis (MF), where standard treatments start to fail, leaving patients and their families searching desperately for new hope. That's the harsh reality for many, but today, a promising breakthrough is underway that could change everything—let's dive into how iOnctura is stepping up to tackle this challenge head-on.
iOnctura, a innovative clinical-stage biopharmaceutical firm dedicated to fighting overlooked and tough-to-treat cancers, has just reached a key milestone by administering the first dose to a patient in their Phase I/II HEMA-MED clinical trial (NCT06887803, available at https://clinicaltrials.gov/study/NCT06887803). This study is focused on assessing both the safety and potential effectiveness of combining roginolisib—a targeted PI3Kδ inhibitor—with ruxolitinib in individuals with MF who no longer benefit from Janus kinase (JAK) inhibitors. For those new to this, PI3Kδ is part of a signaling pathway that can go haywire in cancer cells, promoting their growth, while JAK inhibitors like ruxolitinib are the go-to drugs for managing MF symptoms by blocking inflammation and abnormal cell production in the bone marrow.
What makes this approach so exciting is its dual-target strategy: by hitting both the PI3Kδ and JAK pathways, the treatment aims to hit the disease from multiple angles. These pathways play complementary roles in MF, where JAK inhibitors often lose their punch over time due to resistance mechanisms. Think of it like fortifying a wall with two layers of defense—instead of one drug fighting alone, this combo could bypass resistance and deliver better results. And this is the part most people miss: while single therapies have improved lives, combining them thoughtfully might just unlock responses in patients who've run out of options.
Adding to the buzz, iOnctura will unveil fresh non-clinical evidence at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida (details at https://www.hematology.org/meetings/annual-meeting). Scheduled for Sunday, December 7, at 6:00 PM EST, a poster session will spotlight trial updates, while another on Monday, December 8, at 6:00 PM EST, will share data from lab-based models of MF. These findings show that roginolisib works effectively on its own against MF cells in ex-vivo setups (that's basically testing in cells taken directly from patients, outside the body) and teams up powerfully with JAK inhibitors like ruxolitinib or momelotinib for an amplified anti-cancer punch.
This trial isn't happening in isolation—it's a vital piece of iOnctura's broader push to explore roginolisib's safety and tumor-fighting potential across various solid tumors and blood cancers. As Dr. Michael Lahn, iOnctura's Chief Medical Officer, puts it: 'From the non-clinical insights we're sharing at ASH, we're optimistic that dual inhibition of PI3Kδ and JAK could create a powerful synergy in MF. Past PI3Kδ blockers fell short due to side effects that made them hard to use, but roginolisib's cleaner profile changes the game.'
To break it down for beginners: the PI3K-Akt pathway is like a faulty switch in cells that fuels cancer growth and spread [1]. In MF specifically, this pathway often kicks into overdrive as a way for the disease to resist JAK treatments [2]. By dialing it back with roginolisib, researchers hope to restore sensitivity and spark meaningful improvements. The ASH data backs this up, highlighting roginolisib's solo activity on MF cell lines and patient-derived cells, plus its teamwork with JAK drugs to supercharge the effects—evidence that's fueling the HEMA-MED trial.
Professor Alessandro Vannucchi, a leading hematologist and head of the Center for Research and Innovation in Myeloproliferative Neoplasms (CRIMM) at the University of Florence in Italy, who is spearheading the HEMA-MED study, shares this enthusiasm: 'For MF patients, responses to ruxolitinib can be lackluster from the start or fade as resistance builds. Roginolisib's unique way of working and its gentler side effects make it an ideal teammate for ruxolitinib. Together, they might deliver longer-lasting benefits and shake up how we approach this tough, uncommon illness.'
But here's where it gets controversial: while this combo sounds revolutionary, some experts debate whether layering on PI3Kδ inhibition will truly outperform evolving single-agent strategies or if it risks unnecessary complexity and side effects. Is the synergy worth the added variables, or should we stick to refining what's already proven? iOnctura isn't stopping at MF—ASH will also feature trial-in-progress posters on roginolisib for peripheral T-cell lymphoma and chronic lymphocytic leukemia (CLL), showing the drug's versatility.
Here's a rundown of iOnctura's poster lineup at the 67th ASH Annual Meeting in Orlando, Florida, USA:
A. Vannucchi et al. Trial in Progress: Sunday, December 7, 06:00 PM - 08:00 PM EST
Abstract 25-4153: Investigating roginolisib paired with ruxolitinib for MF patients unresponsive to JAK inhibitors (HEMA-MED)M. Balliu et al.: Monday, December 8, 06:00 PM - 08:00 PM EST
Abstract 25-7102: How the targeted PI3Kδ blocker roginolisib enhances ruxolitinib's impact on stem cells from untreated and JAK-resistant MF patientsD. Sibon et al. Trial in Progress: Sunday, December 7, 06:00 PM - 08:00 PM EST
Abstract 25-11050: PlatΤform: A collaborative, multi-arm academic trial testing new drugs and combos for relapsed or refractory peripheral T-cell lymphomasJ. Brown et al. Trial in Progress: Sunday, December 7, 06:00 PM - 08:00 PM EST
Abstract 25-7765: Roginolisib (IOA-244), a pill-based selective PI3Kδ inhibitor, combined with venetoclax and rituximab for relapsed CLL patients
A Quick Primer on Myelofibrosis (MF)
MF is a scarce type of blood disorder in the myeloproliferative neoplasm family, where genetic mutations cause abnormal cell buildup and scarring in the bone marrow, disrupting normal blood production. It affects about 0.5 people per 100,000 worldwide each year [3], leading to fatigue, anemia, enlarged spleen, and worse. JAK inhibitors have been a game-changer, easing symptoms and boosting daily life for many, but roughly 50% of users stop within three years due to the disease advancing, intolerable side effects, or resistance-driven complications and fatalities [4],[5],[6]. For example, as the cancer evolves, it finds workarounds around the JAK block, leaving patients vulnerable—highlighting why innovative combos like this trial are so crucial.
Details on the HEMA-MED Clinical Trial
This forward-looking, multi-site, open-label Phase I/II trial with a single treatment arm is split into two phases. The first phase will recruit 13 participants to evaluate the safety of merging roginolisib with ruxolitinib. Building on that, the second phase adds another 13 patients, totaling 26, to weigh the overall benefits against risks. Beyond safety, the study tracks secondary goals like reductions in blood markers, spleen size, and MF symptoms. It also explores outcomes tied to roginolisib's specific action mechanism, such as how it influences key cellular pathways.
Meet iOnctura
iOnctura is at the forefront of precision oncology, developing pioneering small-molecule drugs to extend survival and enhance quality of life for those battling underserved cancers. Their flagship, roginolisib, stands out as a non-ATP competitive, allosteric PI3Kδ modulator—meaning it binds to a unique spot on the protein to tweak its activity precisely, avoiding the pitfalls of older inhibitors that caused severe immune issues. This fresh allosteric method offers potent anti-cancer effects with better tolerability. Currently, roginolisib is in several Phase II trials for both solid tumors and blood cancers. The company calls Amsterdam, Netherlands, home, with outposts in Geneva, Switzerland, and Cambridge, MA, USA, supported by top-tier investors like Syncona, M Ventures, Inkef Capital, EIC Fund, VI Partners, Schroders Capital, and XGEN Venture.
All About Roginolisib
As a trailblazing allosteric PI3Kδ inhibitor that's taken orally, roginolisib features a novel structure and binding approach. Unlike traditional blockers that compete directly for the enzyme's active site, this one modulates from the side, delivering accuracy without the harsh backlash seen in earlier versions. The PI3K pathway is notoriously overactive in countless cancers, driving uncontrolled growth—making it a prime target. Early Phase I results have been encouraging, showing clinical benefits in solid and blood cancers, like nearly doubling survival rates versus past benchmarks in uveal melanoma, a rare eye cancer. iOnctura is strategically advancing it, with the Phase II OCULE-01 trial in uveal melanoma kicking off in March 2025, PULMO-01 in non-small cell lung cancer in May 2025, and HEMA-MED in MF this November 2025.
For more details, reach out to iOnctura's Corporate Press Office at emailprotected.
References:
[1] He et al., 2021
[2] Moyo et al., 2023 (https://aacrjournals.org/clincancerres/article-abstract/29/13/2375/727355/PI3K-Inhibition-Restores-and-Amplifies-Response-to?redirectedFrom=fulltext)
[3] Titmarsh et al., 2014 (https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.23690)
[4] Verstovsek et al., 2015
[5] Kuykendall et al., 2018
[6] Newberry et al., 2017 (https://pubmed.ncbi.nlm.nih.gov/28674026/)
Logo - https://mma.prnewswire.com/media/2736715/5654096/iOnctura_Logo.jpg
SOURCE iOnctura
So, what do you think—could roginolisib's allosteric twist be the missing link in conquering MF resistance, or does it raise more questions than answers about combo therapies? Share your thoughts in the comments: agree that this dual-pathway attack is the future, or skeptical about its real-world impact? Your voice could spark the next big conversation in cancer research.
